drugset
drugset / Trial / NCT03909529

Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)

NCT03909529 ↗

Phase 1 Completed 28 enrolled CMP Development, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

An open label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, crossover oral drug-drug interaction study of spironolactone (perpetrator) and Digoxin (substrate drug) in healthy adult human subjects under fasting condition.

Timeline

Start
2019-03-10
Primary completion
2019-04-19
Completion
2019-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 250 ug Oral
Subject Spironolactone Small molecule 100 mg Oral

Indications

No indication recorded.